Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Microbot Medical Inc. (NASDAQ: MBOT), a commercial stage medical device company focused on the LIBERTY Endovascular Robotic System. Through these filings, investors can review how the company reports material events, financing transactions, intellectual property developments and key commercialization steps for its endovascular robotics platform.
Microbot Medical uses current reports on Form 8-K to disclose significant milestones, including FDA 510(k) clearance for the LIBERTY System, the start of its limited market release in the U.S., and the first hospital adoption of LIBERTY for patient care at Emory University Hospital. Other 8-K filings describe partnerships with a U.S.-based third-party logistics provider to support commercialization, as well as the company’s exhibition of LIBERTY at major medical meetings.
Several 8-K filings also detail capital markets activity, such as the exercise of outstanding preferred investment options, issuance of new short-term preferred investment options and related gross proceeds. In these documents, Microbot Medical outlines intended uses of funds, including continued development, commercialization and regulatory activities for the LIBERTY Robotic System, potential acquisitions of complementary assets or products, expansion of applications derived from its IP portfolio, and working capital and general corporate purposes.
Additional filings address intellectual property events, such as the granting of the company’s first patent in Japan covering core LIBERTY System technology, and certain compensation decisions for executives and non-management directors. On Stock Titan, these filings are updated as they are made available through EDGAR, and AI-powered summaries can help explain the context and key points of each document, from material event disclosures to financing terms and governance changes related to MBOT.
Microbot Medical Inc. director Aileen Ptucha Stockburger received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and are scheduled to expire on April 1, 2036.
Microbot Medical Inc. director Madden Martin J. received a grant of stock options representing 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
This is a compensation-related award, not an open-market purchase or sale, and leaves the director holding 10,000 options following the transaction.
Microbot Medical Inc. director Wenderow Tal Baruch received a grant of stock options, giving the right to buy 10,000 shares of common stock. The options have an exercise price of $2.37 per share and expire on April 1, 2036. Following this grant, Baruch holds stock options covering 10,000 shares directly.
Microbot Medical Inc. director David James Wilson received a grant of stock options covering 10,000 shares of common stock. The options were awarded at an exercise price of $2.37 per share, carry no upfront cost, and were granted on April 1, 2026.
These options give him the right to buy 10,000 shares of Microbot Medical common stock at $2.37 per share until their expiration on April 1, 2036. After this grant, he holds 10,000 stock options directly, with no additional derivative positions shown in this filing.
Microbot Medical Inc. director Burell Scott R reported receiving a grant of stock options. On April 1, 2026, he was awarded options to acquire 10,000 shares of common stock at an exercise price of $2.37 per share, expiring on April 1, 2036. Following this grant, he holds stock options covering 10,000 underlying shares directly.
Microbot Medical Inc. director Laxminarain Prattipati received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
Following this grant, Prattipati holds stock options for 10,000 shares directly. This is a compensation-related award, not an open‑market purchase or sale of Microbot Medical common stock.
Microbot Medical provides an in-depth annual update on its transition from R&D to commercialization of the FDA‑cleared LIBERTY® Endovascular Robotic Surgical System, its sole product. The company began a limited U.S. market release in November 2025 and is planning a full launch around the Society of Interventional Radiology conference in April 2026.
LIBERTY is a compact, single‑use, remotely operated robotic system aimed at peripheral endovascular procedures, with telerobotic capabilities still under evaluation. Microbot reports no revenues through December 31, 2025 and continues to incur significant operating losses while investing heavily in R&D, manufacturing scale‑up and commercial infrastructure.
The company received ISO 13485:2016 certification in 2024 to support CE Marking, and anticipates CE Mark approval for LIBERTY in the second half of 2026, enabling European sales. Operations rely on third‑party manufacturing, Israeli government grants, and a 43‑person workforce in the U.S. and Israel, while management highlights ongoing capital needs and detailed risk factors, including geopolitical risks tied to recent Middle East hostilities.
Microbot Medical Inc. filed an update highlighting real-world use of its LIBERTY Endovascular Robotic System at Emory Healthcare. Emory’s interventional radiologists successfully performed robotic peripheral endovascular procedures, including the world’s first robotic prostatic artery embolization for benign prostatic hyperplasia and robotic Y-90 radioembolization mapping for liver cancer.
The LIBERTY System is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision, reduce radiation exposure and physical strain, and improve procedural efficiency. Microbot began a Limited Market Release in November 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026 to further drive adoption.
Microbot Medical Inc. reported that a pivotal clinical study of its LIBERTY® Endovascular Robotic System has been published in the peer‑reviewed Journal of Vascular and Interventional Radiology. The article analyzes the ACCESS-PVI multicenter feasibility study, whose lead principal investigator was Dr. Francois Cornelis.
The company notes that publication follows completion of the ACCESS-PVI study in 2025 and its presentation at the Society of Interventional Radiology meeting. LIBERTY received U.S. FDA clearance in September 2025 for peripheral endovascular procedures. Microbot began a limited market release in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. furnished an 8-K to share that it will participate in the Roth Annual Growth Conference in Laguna Niguel, California from March 22-24, 2026. CEO Harel Gadot will join a live fireside Q&A on March 23, with a webcast available through the company’s website.
The company also released updated investor presentation materials, accessible online, highlighting progress with its LIBERTY Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, moving from a limited market release that began in late 2025 toward a planned full market release at the SIR conference in April 2026.